Biology Reference
In-Depth Information
in multiple myeloma patients undergoing autologous bone
marrow transplantation. Int J Cancer 2007;
187. Ma S, Egyhazi S, Ueno T, et al. O6-methylguanine-DNA-meth-
yltransferase expression and gene polymorphisms in relation to
chemotherapeutic response in metastatic melanoma. Br J Cancer
2003;
:1036
e
45.
170. Rosell R, Taron M, Camps C, Lopez-Vivanco G. Influence of
genetic markers on survival in non-small cell lung cancer. Drugs
Today (Barc) 2003;
120
:1517
e
23.
188. Edara S, Kanugula S, Goodtzova K, Pegg AE. Resistance of the
human O6-alkylguanine-DNA alkyltransferase containing argi-
nine at codon 160 to inactivation by O6-benzylguanine. Cancer
Res 1996;
89
:775
e
86.
171. Petty WJ, Knight SN, Mosley L, et al. A pharmacogenomic study of
docetaxel and gemcitabine for the initial treatment of advanced
non-smallcelllungcancer.JThoracOncol2007;
39
:197
e
202.
172. Graves RJ, Li BF, Swann PF. Repair of synthetic oligonucleotides
containing O6-methylguanine, O6-ethylguanine and O4-methyl-
thymine, by O6-alkylguanine-DNA alkyltransferase. IARC Sci
Publ; 1987:41
e
3.
173. Gonzaga PE, Brent TP. Affinity purification and characterization
of human O6-alkylguanine-DNA alkyltransferase complexed
with BCNU-treated, synthetic oligonucleotide. Nucleic Acids Res
1989;
2
:5571
e
5.
189. PeggAE, Kanugula S, Edara S, PaulyGT,Moschel RC, GoodtzovaK.
Reaction of O6-benzylguanine-resistant mutants of human O6-
alkylguanine-DNA alkyltransferase with O6-benzylguanine in oli-
godeoxyribonucleotides. JBiolChem1998;
56
:10863
e
7.
190. Xu-Welliver M, Leitao J, Kanugula S, Meehan WJ, Pegg AE. Role
of codon 160 in the sensitivity of human O6-alkylguanine-DNA
alkyltransferase
273
to O6-benzylguanine.
Biochem Pharmacol
:6581
e
90.
174. Esteller M, Herman JG. Generating mutations but providing
chemosensitivity: the role of O6-methylguanine DNA methyl-
transferase in human cancer. Oncogene 2004;
17
:1279
e
85.
191. Margison GP, Heighway J, Pearson S, et al. Quantitative trait
locus analysis reveals two intragenic sites that influence O6-
alkylguanine-DNA alkyltransferase activity in peripheral blood
mononuclear cells. Carcinogenesis 2005;
1999;
58
:1
e
8.
175. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the
DNA-repair gene MGMT and the clinical response of gliomas to
alkylating agents. N Engl J Med 2000;
23
:1473
e
80.
192. Ochsenbein AF, Schubert AD, Vassella E, Mariani L. Quantitative
analysis of O(6)-methylguanine DNA methyltransferase (MGMT)
promoter methylation in patients with low-grade gliomas.
J Neurooncol; 2010. September 21 [Epub ahead of print].
193. Busch C, Geisler J, Lillehaug JR, Lonning PE. MGMT expression
levels predict disease stabilisation, progression-free and overall
survival in patients with advanced melanomas treated with
DTIC. Eur J Cancer 2010;
26
:1350
e
4.
176. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hyper-
methylation of the DNA repair enzyme methyltransferase
predicts response to temozolomide in primary gliomas. Clin
Cancer Res 2004;
343
:4933
e
8.
177. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumor O6
methylguanine-DNA methyltransferase levels with survival of
malignant astrocytoma patients treated with bis-chloroethylni-
trosourea: a Southwest Oncology Group study. J Clin Oncol
1998;
10
:2127
e
33.
194. Hassel JC, Sucker A, Edler L, et al. MGMT gene promoter
methylation correlates with tolerance of temozolomide treatment
in melanoma but not with clinical outcome. Br
46
:3310
e
5.
178. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and
benefit
16
J Cancer
:820
e
6.
195. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and
adriamycin resistance are associated with MutLalpha and
mismatch repair deficiency in an ovarian tumor cell line. J Biol
Chem 1996;
2010;
103
from temozolomide in glioblastoma. N Engl
J Med
:997
e
1003.
179. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates
the predictive value of O-6-methylguanine-DNA methyl-
transferase promoter methylation in glioblastoma patients
treated with temozolomide. Clin Cancer Res 2004;
2005;
352
:19645
e
8.
196. Friedman HS, Johnson SP, Dong Q, et al. Methylator resistance
mediated by mismatch repair deficiency in a glioblastoma mul-
tiforme xenograft. Cancer Res 1997;
271
:1871
e
4.
180. Sabharwal A, Middleton MR. Exploiting the role of O6-methyl-
guanine-DNA-methyltransferase (MGMT)
10
:2933
e
6.
197. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations
override alkyltransferase in conferring resistance to temozolo-
mide but not
57
in cancer
therapy.
:355
e
63.
181. Wiencke JK, Aldape K, McMillan A, et al. Molecular features of
adult glioma associated with patient race/ethnicity, age, and
a polymorphism in O6-methylguanine-DNA-methyltransferase.
Cancer Epidemiol Biomarkers Prev 2005;
Curr Opin Pharmacol 2006;
6
to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res
:5375
e
9.
198. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch
repair
1996;
56
:1774
e
83.
182. Yang M, Coles BF, Caporaso NE, Choi Y, Lang NP, Kadlubar FF.
Lack of association between Caucasian lung cancer risk and O6-
methylguanine-DNA methyltransferase-codon 178 genetic poly-
morphism. Lung Cancer 2004;
14
in
acquired resistance
to
cisplatin. Cancer Res
:3087
e
90.
199. Aebi S, Fink D, Gordon R, et al. Resistance to cytotoxic drugs in
DNA mismatch
1996;
56
repair-deficient
cells. Clin Cancer Res
:281
e
6.
183. Abe M, Inoue R, Suzuki T. A convenient method for genotyping
of human O6-methylguanine-DNA methyltransferase poly-
morphism. Jpn J Hum Genet 1997;
44
:1763
e
7.
200. Hamelin R, Chalastanis A, Colas C, et al. [Clinical and molecular
consequences of microsatellite instability in human cancers.]. Bull
du cancer 2008;
1997;
3
:425
e
8.
184. Otsuka M, Abe M, Nakabeppu Y, Sekiguchi M, Suzuki T. Poly-
morphism in the human O6-methylguanine-DNA methyl-
transferase gene detected by PCR-SSCP analysis. Pharmacogenetics
1996;
42
:121
e
32.
201. Bendardaf R, Lamlum H, Ristamaki R, Korkeila E, Syrjanen K,
Pyrhonen S. Mismatch repair status is a predictive factor of
tumour response to 5-fluorouracil and irinotecan chemotherapy
in patients with advanced colorectal
95
:361
e
3.
185. Imai Y, Oda H, Nakatsuru Y, Ishikawa T. A polymorphism at
codon 160 of human O6-methylguanine-DNA methyltransferase
gene in young patients with adult type cancers and functional
assay. Carcinogenesis 1995;
6
cancer. Tumour Biol
:212
e
20.
202. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the
prediction of benefit from adjuvant fluorouracil chemotherapy in
colorectal cancer. Gut 2006;
2007;
28
:2441
e
5.
186. Schwarzl SM, Smith JC, Kaina B, Efferth T. Molecular modeling
of O6-methylguanine-DNA methyltransferase mutant proteins
encoded by single nucleotide polymorphisms. Int J Mol Med
2005;
16
:848
e
55.
203. Kakar S, Aksoy S, Burgart LJ, Smyrk TC. Mucinous carcinoma of
the colon: correlation of
55
loss of mismatch repair enzymes
with clinicopathologic
features
and survival. Mod Pathol
16
:553
e
7.
2004;
17
:696
e
700.
